A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

Administered By

Awarded By

Contributors

Start/End

  • July 15, 2020 - March 30, 2023